Table 1.
T lymphocyte surface protein | Tumor cell surface protein with which this T lymphocyte protein interacts | Effect of this interaction on the T cell | Comment |
---|---|---|---|
T cell receptor | MHC | Stimulation | First step in the activation of T cells to effector T cells |
CD28 | B 7.1 and B 7.2 | Co-stimulation | Second step in the activation of T cells to effector T cells |
CTLA4 (Cytotoxic T lymphocyte antigen 4) | B 7.1 and B 7.2 | Prevention of co-stimulation (by blocking the B 7 proteins from interacting with CD28 proteins) | CTLA4 is the target for Ipilimumab, which blocks CTLA4 and thus allows the uninhibited interaction of CD28 with B 7 molecules leading to co-stimulation of T cells |
PD-1 (Programmed death-1) | PD-L1 (Programmed death-ligand 1) | Inactivation | PD-1 and PD-L1 are targets for check point inhibitors which prevent the interaction of PD-1 with PD-L1 and thus prevent the inactivation of T cells |
Notes: Data from Preusser et al.17